Kivizidiale (Timolol, Travoprost)

Timolol blocks beta‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Travoprost mimics prostaglandin F2α, enhancing uveoscleral outflow of fluid from the eye. Together they provide a dual mechanism that more effectively lowers intra‑ocular pressure than either agent alone.

The prescribed dose is determined by the treating ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily, but the exact regimen should follow the clinician’s instructions and may be adjusted based on response.

Safety data for Kivizidiale in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks and discuss any concerns with the patient before prescribing.

To request Kivizidiale, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with monotherapy agents such as latanoprost or timolol alone, Kivizidiale offers combined pressure‑lowering mechanisms, often achieving greater IOP reduction. This can simplify treatment by reducing the need for multiple separate drops, though individual response varies.

Store Kivizidiale at room temperature, preferably below 25 °C, in the original container. Protect the bottle from direct light and moisture, and keep the cap tightly closed to maintain sterility.

Kivizidiale is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of each prescribed eye. Avoid touching the tip of the bottle to the eye or any surface.

Serious adverse events include severe allergic reactions (e.g., angioedema), marked bradycardia or heart block, bronchospasm in susceptible individuals, and significant systemic hypotension. Patients should seek immediate medical attention if they experience any of these symptoms.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients, as well as those with severe asthma, chronic obstructive pulmonary disease, or advanced heart block. Caution is also advised for individuals with uncontrolled cardiovascular disease.